| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED APRIL 2014. Refer to TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (replaced TA309) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | pemetrexed (Alimta®) | |
| Formulation | powder for concentrate for solution for infusion | |
| Reference number | 1426 | |
| Indication | Monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following induction therapy with pemetrexed in combination with cisplatin |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Date of issue | 08/03/2012 | |
| NICE guidance | TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (replaced TA309)
|
|